A likely protective effect of dimethyl itaconate on cerebral ischemia/reperfusion injury

Int Immunopharmacol. 2019 Dec:77:105924. doi: 10.1016/j.intimp.2019.105924. Epub 2019 Oct 31.

Abstract

As a membrane-permeable derivative of itaconate, dimethyl itaconate (DMI) was recently showed to limit inflammatory response of activated macrophages, and to decrease the generation of reactive oxygen species and reduce cardiac ischemia/reperfusion injury. However, the effect of DMI in the context of cerebral ischemia/reperfusion injury remains unclear. Here, we treated the transient middle cerebral artery occlusion (tMCAO) mice with DMI or saline at the beginning of occlusion, and allowed them to recover for 3 days. We found that DMI obviously decreased the neurologic deficit score. Further, DMI significantly inhibited the toxic conversion of the peri-infarct microglia, and decreased the protein level of interleukin 1β. The present findings suggest that DMI might be recognized as a promising candidate for the treatment of ischemic stroke.

Keywords: Cerebral ischemia/reperfusion injury; Dimethyl itaconate; Microglia.

MeSH terms

  • Animals
  • Infarction, Middle Cerebral Artery / drug therapy*
  • Male
  • Mice, Inbred C57BL
  • Neuroprotective Agents / therapeutic use*
  • Reperfusion Injury / drug therapy*
  • Succinates / therapeutic use*

Substances

  • Neuroprotective Agents
  • Succinates
  • dimethyl itaconate